JP2024509251A5 - - Google Patents

Info

Publication number
JP2024509251A5
JP2024509251A5 JP2023554927A JP2023554927A JP2024509251A5 JP 2024509251 A5 JP2024509251 A5 JP 2024509251A5 JP 2023554927 A JP2023554927 A JP 2023554927A JP 2023554927 A JP2023554927 A JP 2023554927A JP 2024509251 A5 JP2024509251 A5 JP 2024509251A5
Authority
JP
Japan
Prior art keywords
antigen
viral vector
recombinant viral
binding
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023554927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509251A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/079047 external-priority patent/WO2022188689A1/zh
Publication of JP2024509251A publication Critical patent/JP2024509251A/ja
Publication of JP2024509251A5 publication Critical patent/JP2024509251A5/ja
Pending legal-status Critical Current

Links

JP2023554927A 2021-03-08 2022-03-03 デュアルウイルスベクター系による抗体送達 Pending JP2024509251A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110252231.1 2021-03-08
CN202110252231 2021-03-08
PCT/CN2022/079047 WO2022188689A1 (zh) 2021-03-08 2022-03-03 使用双重病毒载体系统递送抗体

Publications (2)

Publication Number Publication Date
JP2024509251A JP2024509251A (ja) 2024-02-29
JP2024509251A5 true JP2024509251A5 (https=) 2025-03-11

Family

ID=83226363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023554927A Pending JP2024509251A (ja) 2021-03-08 2022-03-03 デュアルウイルスベクター系による抗体送達

Country Status (6)

Country Link
US (1) US20240148903A1 (https=)
EP (1) EP4306131A4 (https=)
JP (1) JP2024509251A (https=)
KR (1) KR20230154074A (https=)
CN (1) CN116981485A (https=)
WO (1) WO2022188689A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118139628A (zh) * 2021-08-23 2024-06-04 阿维麦克思生物制药公司 用于转基因表达的组合物和方法
WO2025155774A2 (en) * 2024-01-19 2025-07-24 Amgen Inc. Vector engineering strategies to enhance volumetric productivity and decrease impurity formation across a diverse set of modalities
WO2025155776A1 (en) * 2024-01-19 2025-07-24 Amgen Inc. Expression vector systems with two copies of light chain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO2000025574A1 (en) * 1998-10-30 2000-05-11 Thomas Jefferson University Production of biomedical peptides and proteins in plants using plant virus vectors
AU2001238079A1 (en) * 2000-02-09 2001-08-20 Med Immune, Inc. Antibody gene therapy with adeno-associated viral vectors
DK1716233T3 (da) * 2004-01-30 2009-10-26 Maxygen Holdings Ltd Reguleret stopkodongennemlæsning
US7714119B2 (en) 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
EP2325322A1 (en) * 2009-11-23 2011-05-25 4-Antibody AG Retroviral vector particles and methods for their generation and use
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
CN104011080B (zh) * 2011-12-22 2017-10-20 弗·哈夫曼-拉罗切有限公司 用于真核细胞的全长抗体展示系统及其用途
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
CN102634542B (zh) * 2012-04-12 2014-03-26 北京工业大学 一种表达人抗体全基因的重组腺相关病毒(rAAV)载体及其方法
US9708601B2 (en) * 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
WO2018129331A1 (en) 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
MY202480A (en) 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof

Similar Documents

Publication Publication Date Title
JP2024509251A5 (https=)
JP2021533795A5 (https=)
US7714119B2 (en) AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
CA2348382C (en) Chimeric parvovirus vectors and methods of making and administering the same
JP2020048571A5 (https=)
JP2021513355A5 (https=)
JP2023171525A (ja) Ａａｖキメラ
JP2025119015A (ja) 改変ウイルス粒子およびその使用
JP2022544004A (ja) 操作された核酸調節エレメントならびにその使用方法
JP2020520643A5 (https=)
JP2022523679A5 (https=)
JP2002518050A (ja) Ａａｖの構造タンパク質、その製造及び用途
CA3129506A1 (en) Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers
US20240168018A1 (en) Methods for detecting and evaluating viruses and virus-like particles
US20250340621A1 (en) Methods of aav therapy
JP2025517628A (ja) 新規の組換えａａｖ ｖｐ２融合ポリペプチド
WO2021255590A1 (en) An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof
CN116981485A (zh) 使用双重病毒载体系统递送抗体
AR123948A1 (es) ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
US20240050476A1 (en) Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer
EP4602054A1 (en) Fusion proteins comprising a cell surface marker specific vhh
Mann et al. Enhanced transduction of P2X7-expressing cells with recombinant rAAV vectors
Kuklik Development of a novel capsid modified AAV vector platform enabling retargeting by modular bispecific antibody binding
KR20250141727A (ko) 항-aav 입자 항체 검출 방법
WO2026080176A1 (en) Scfv-and fab-modified aav capsids and uses thereof